Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Hengrui Signs $706 Million Deal Sending US Rights for EZH2 Inhibitor to Treeline

publication date: Feb 15, 2023

Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Treeline is an 18-month-old small molecule pharma that has raised $473 million for novel drug development. Hengrui has filed a China IND for SHR2554 in patients with peripheral T-cell lymphoma (PTCL), though the company also says it will publish results from a pre-Phase I clinical trial in the Lancet. Hengrui will receive an upfront payment of $11 million and milestone of up to $695 million, plus royalties. More details....

Stock Symbol: (SHA: 600275)

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital